Squarepoint’s Galectin Therapeutics GALT Stock Holding History

Squarepoint’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$109K	Buy	+28,193	New	+$109K	﹤0.01%	4197
2026 Q1	–	Sell	-16,462	Closed	-$68.5K	–	4503
2025 Q4	$68.5K	Buy	+16,462	New	+$86.7K	﹤0.01%	4100
2024 Q4	–	Sell	-27,435	Closed	-$75.4K	–	5177
2024 Q3	$75.4K	Sell	27,435 -56,639	-67%	-$139K	﹤0.01%	3930
2024 Q2	$190K	Buy	84,074 +36,139	+75%	+$110K	﹤0.01%	3674
2024 Q1	$115K	Buy	+47,935	New	+$90.7K	﹤0.01%	3772
2022 Q1	–	Sell	-13,182	Closed	-$27K	–	3088
2021 Q4	$27K	Sell	13,182 -26,009	-66%	-$74.3K	﹤0.01%	3076
2021 Q3	$152K	Sell	39,191 -16,937	-30%	-$57.4K	﹤0.01%	2586
2021 Q2	$180K	Buy	+56,128	New	+$200K	﹤0.01%	2872
2020 Q1	–	Sell	-14,537	Closed	-$42K	–	2094
2019 Q4	$42K	Buy	14,537 +636	+5%	+$2.21K	﹤0.01%	2402
2019 Q3	$51K	Buy	13,901 +3,788	+37%	+$13.7K	﹤0.01%	2239
2019 Q2	$42K	Buy	+10,113	New	+$43.8K	﹤0.01%	2290
2018 Q4	–	Sell	-29,525	Closed	-$177K	–	2042
2018 Q3	$177K	Buy	29,525 +12,947	+78%	+$71.2K	﹤0.01%	1800
2018 Q2	$105K	Buy	+16,578	New	+$80.7K	﹤0.01%	1638

Other funds holding GALT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Geneos Wealth Management Englewood, Colorado $5.32B AUM 16.49% 1-Year Est. Return

Sovran Advisors San Diego, California $1.45B AUM 13.87% 1-Year Est. Return

Retirement Guys Formula Maumee, Ohio $269M AUM 17.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Squarepoint's GALT Position: Q3 2026 in Review

Squarepoint opened a new position in Galectin Therapeutics (GALT) in Q3 2026: 28,193 shares worth $109K. The stake represents ﹤0.01% of the portfolio and ranks #4197 among its holdings. This is a return to the name: Squarepoint previously reported a position in GALT as recently as Q4 2025.

Squarepoint first reported a position in GALT in Q2 2018 and has held it in 13 quarters since. The position peaked at $190K in Q2 2024. 63 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

Squarepoint held 28,193 shares of Galectin Therapeutics worth $109K as of Q3 2026.
Galectin Therapeutics was a new Squarepoint position in Q3 2026.
Galectin Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4197 holding.
Squarepoint first reported a position in Galectin Therapeutics in Q2 2018 and has held it in 13 quarters since.
Squarepoint's Galectin Therapeutics position peaked at $190K in Q2 2024.
63 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.